ITEOS THERAPEUTICS INC (ITOS)
US46565G1040 - Common Stock
Overall ITOS gets a fundamental rating of 4 out of 10. We evaluated ITOS against 572 industry peers in the Biotechnology industry. ITOS has a great financial health rating, but its profitability evaluates not so good. ITOS is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ITOS had negative earnings in the past year.
ITOS had a negative operating cash flow in the past year.
In multiple years ITOS reported negative net income over the last 5 years.
ITOS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ITOS's Return On Assets of -16.77% is amongst the best of the industry. ITOS outperforms 80.53% of its industry peers.
ITOS has a Return On Equity of -19.19%. This is amongst the best in the industry. ITOS outperforms 85.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.77% | ||
| ROE | -19.19% | ||
| ROIC | N/A |
ROA(3y)6.73%
ROA(5y)-15.75%
ROE(3y)11.27%
ROE(5y)-29.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ITOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ITOS has more shares outstanding than it did 1 year ago.
ITOS has more shares outstanding than it did 5 years ago.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.11 indicates that ITOS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ITOS has a better Altman-Z score (2.11) than 72.39% of its industry peers.
There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.11 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
A Current Ratio of 14.80 indicates that ITOS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 14.80, ITOS belongs to the top of the industry, outperforming 89.38% of the companies in the same industry.
A Quick Ratio of 14.80 indicates that ITOS has no problem at all paying its short term obligations.
The Quick ratio of ITOS (14.80) is better than 89.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.8 | ||
| Quick Ratio | 14.8 |
3. Growth
3.1 Past
ITOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -80.06%.
Looking at the last year, ITOS shows a very negative growth in Revenue. The Revenue has decreased by -47.37% in the last year.
EPS 1Y (TTM)-80.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-47.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 4.09% on average over the next years.
ITOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.14% yearly.
EPS Next Y-8.35%
EPS Next 2Y-16.98%
EPS Next 3Y-10.88%
EPS Next 5Y4.09%
Revenue Next Year263.9%
Revenue Next 2Y-27.1%
Revenue Next 3Y5.62%
Revenue Next 5Y48.14%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ITOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITOS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ITOS's earnings are expected to decrease with -10.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.98%
EPS Next 3Y-10.88%
5. Dividend
5.1 Amount
ITOS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ITEOS THERAPEUTICS INC
NASDAQ:ITOS (1/14/2025, 8:00:02 PM)
Premarket: 7.8 +0.14 (+1.83%)7.66
-0.14 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.98%
Inst Owner Change0%
Ins Owners0.78%
Ins Owner Change1.58%
Market Cap279.82M
Analysts85
Price Target25.5 (232.9%)
Short Float %4.14%
Short Ratio2.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)33.6%
Min EPS beat(2)-15.79%
Max EPS beat(2)82.99%
EPS beat(4)3
Avg EPS beat(4)25.76%
Min EPS beat(4)-15.79%
Max EPS beat(4)82.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1615.69%
Min Revenue beat(2)-100%
Max Revenue beat(2)3331.37%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.54%
PT rev (3m)-32.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.86%
EPS NY rev (1m)12.37%
EPS NY rev (3m)15.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.99 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.44 | ||
| P/tB | 0.44 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.15
EYN/A
EPS(NY)-4.31
Fwd EYN/A
FCF(TTM)-3.29
FCFYN/A
OCF(TTM)-3.21
OCFYN/A
SpS0.96
BVpS17.29
TBVpS17.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.77% | ||
| ROE | -19.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)6.73%
ROA(5y)-15.75%
ROE(3y)11.27%
ROE(5y)-29.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 255.48% | ||
| Cap/Sales | 8.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.8 | ||
| Quick Ratio | 14.8 | ||
| Altman-Z | 2.11 |
F-Score2
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)226.27%
Cap/Depr(5y)175.1%
Cap/Sales(3y)8.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-8.35%
EPS Next 2Y-16.98%
EPS Next 3Y-10.88%
EPS Next 5Y4.09%
Revenue 1Y (TTM)-47.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year263.9%
Revenue Next 2Y-27.1%
Revenue Next 3Y5.62%
Revenue Next 5Y48.14%
EBIT growth 1Y-60.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.79%
EBIT Next 3Y-8.88%
EBIT Next 5YN/A
FCF growth 1Y16.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.82%
OCF growth 3YN/A
OCF growth 5YN/A